← Search & browse all drugs
BLOOD AND BLOOD FORMING ORGANS › ANTITHROMBOTIC AGENTS › ANTITHROMBOTIC AGENTS › Vitamin K antagonists
phenprocoumon
B01AA04
Forms & Strengths
- Tablets: 1mg, 3mg
- Oral anticoagulant formulation
Adult Dosing
- Initial dose: 12-18mg on the first day
- Maintenance dose: 3-12mg/day, depending on INR
- Adjust dose based on INR response
Pediatric Dosing
- Safety and efficacy not established in children
- Use with caution, dose adjustments may be needed
Indications
- Prevention of thromboembolic disorders
- Treatment of deep vein thrombosis
- Pulmonary embolism
- Atrial fibrillation
Mechanism of Action
- Inhibits vitamin K-dependent clotting factors
- Interferes with gamma-carboxylation of clotting factors
- Prolongs blood clotting time
Contraindications
- Hypersensitivity to phenprocoumon
- Pregnancy, especially during the first and third trimesters
- Severe liver disease
- Bleeding disorders
Adverse Reactions
- Bleeding complications
- Hepatotoxicity
- Allergic reactions
- Gastrointestinal upset
Drug Interactions
- Increased bleeding risk with antiplatelet agents
- Altered anticoagulant effect with antibiotics
- Interactions with NSAIDs, aspirin, and other anticoagulants
- Reduced efficacy with vitamin K-containing products
Curated Content: Needs Vetting Before Put to Clinical Use